Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517451 | 0.80 | TRPA1 (0.39) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27882381 | 0.80 | TRPA1 (0.39) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3475483 | 0.78 | HPGD (0.42) | HPGDSMN1; SMN2CYP1A2CYP2C19APLNR | |
| SCHEMBL21050753 | 0.78 | TRPA1 (0.38) | HPGDSMN1; SMN2TRPA1CYP1A2CYP3A4 | |
| SCHEMBL4541186 | 0.77 | HPGD (0.55) | HPGDSMN1; SMN2TRPA1CYP1A2CYP3A4 | |
| SCHEMBL1844481 | 0.77 | HPGD (0.41) | HPGDSMN1; SMN2CYP1A2CYP2C19APLNR | |
| SCHEMBL22034054 | 0.77 | HPGD (0.37) | HPGDSMN1; SMN2TRPA1CYP1A2CYP3A4 | |
| SCHEMBL22972330 | 0.77 | TRPA1 (0.37) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25343385 | 0.75 | HPGD (0.40) | HPGDSMN1; SMN2CYP1A2CYP2C19APLNR | |
| SCHEMBL21598410 | 0.75 | CCR4 (0.37) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2025020191-A1 | STEROID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2025021193-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
| CN-111343987-B | Macrocyclic compounds as TRK kinase inhibitors and uses thereof | 安杰斯制药公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| EP-3807266-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | HPGD 2446/4885SMN1; SMN2 2443/4885TRPA1 4671/4885 |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | PSEN2, MAPT, PNPO | HPGD 875/4885SMN1; SMN2 33/4885TRPA1 2403/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | HPGD 2997/4885SMN1; SMN2 3904/4885TRPA1 4865/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | HPGD 3078/4885SMN1; SMN2 3779/4885TRPA1 2600/4885 |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | GPR3, GPR27, GPR65 | HPGD 1966/4885SMN1; SMN2 802/4885TRPA1 84/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | HPGD 2997/4885SMN1; SMN2 3904/4885TRPA1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.